Elke Mühlberger

SLR14, an immunomodulatory RIG-I agonist, provides broad-spectrum antiviral protection against multiple highly pathogenic negative-sense RNA viruses in vitro and in vivo.

This study identifies RNA structures in Ebola virus mRNAs critical for infection and shows they can be targeted by antisense oligonucleotides.

The paper shows eIF4E3 enables efficient translation of viral mRNAs with short 5' UTRs, unlike the canonical eIF4E1, and identifies this as a mechanism used by viruses like VSV to bypass host translation suppression.

This paper shows PARP14 promotes IFN production and has both antiviral and proviral functions against multiple viruses.

This paper shows that DHODH inhibitors enhance the antiviral effect of 4'-FlU against multiple RNA viruses, including influenza, SARS-CoV-2, and Ebola virus.

The paper identifies MIG-encoded proteins as potential pan-viral drug targets, showing that repurposed anti-cancer drugs target these proteins.

This study uses human stem cell-derived alveolar type 2 cells to model SARS-CoV-2 infection, revealing rapid inflammatory responses and drug efficacy against the virus.

The paper reconstructs signaling and regulatory networks for SARS-CoV-2 infection and identifies potential drug targets by integrating multi-omics data and experimental validation.